Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial

Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial

Source :

• The Lancet [ 0140-6736 ] ; 2000.

Descripteurs français

• Pascal (Inist)
  • Accident cérébrovasculaire, Adulte, Antagoniste, Chimiothérapie, Efficacité traitement, Etude double insu, Evolution, Gavestinel, Glycine, Neuroprotecteur, Personne âgée, Traitement.
• Wicri :
  • topic : Adulte, Personne âgée.

English descriptors

• KwdEn :
  • Acute ischaemic stroke, Acute ischemic stroke, Acute stroke, Acute stroke treatment, Acute stroke trials, Adult, Adverse events, Animal models, Antagonist, Artery occlusion, Barthel, Barthel index, Barthel index score, Barthel index scores, Barthel score, Baseline, Baseline severity, Cerebrospinal fluid, Chemotherapy, Clinical trial, Diener, Double blind study, Drug effect, Elderly, Endpoint, Evolution, Gain americas, Gavestinel, Gavestinel group, Gavestinel placebo, Glaxo wellcome, Global efficacy, Glutamate, Glutamate antagonist, Glycine, Glycine antagonist, Glycine site, Haemorrhage, Haemorrhagic stroke, Hospital discharge, Human beings, Human stroke, Infarct volume, Interim analysis, Intracerebral haemorrhage, Intracranial haemorrhage, Ischaemic, Ischaemic patients, Ischaemic stroke, Ischaemic strokes, John whitehead, Kjell asplund, Lancet, Lees, Liver function tests, Loading dose, Magnetic resonance imaging, Markku kaste, National institute, Neurological disorders, Neurological status, Neuroprotective, Neuroprotective agent, Neuroprotective drugs, Nihss, Nmda, Nmda receptor, Odds ratio, Patients randomised, Placebo, Placebo group, Plasma concentration, Primary analysis, Primary efficacy analysis, Primary efficacy population, Primary endpoint, Primary intracranial haemorrhage, Primary outcome, Primary outcome measure, Randomised, Rankin scale, Rankin score, Receptor, Secondary analyses, Secondary endpoints, Selective antagonist, Small proportion, Stratification variables, Stroke, Stroke onset, Stroke patients, Stroke severity, Study drug, Study medication, Target population, Thrombolytic therapy, Treatment, Treatment efficiency, Treatment groups, Video training.
• Teeft :
  • Acute ischaemic stroke, Acute ischemic stroke, Acute stroke, Acute stroke treatment, Acute stroke trials, Adverse events, Animal models, Antagonist, Artery occlusion, Barthel, Barthel index, Barthel index score, Barthel index scores, Barthel score, Baseline, Baseline severity, Cerebrospinal fluid, Clinical trial, Diener, Drug effect, Endpoint, Gain americas, Gavestinel, Gavestinel group, Gavestinel placebo, Glaxo wellcome, Global efficacy, Glutamate, Glutamate antagonist, Glycine, Glycine antagonist, Glycine site, Haemorrhage, Haemorrhagic stroke, Hospital discharge, Human beings, Human stroke, Infarct volume, Interim analysis, Intracerebral haemorrhage, Intracranial haemorrhage, Ischaemic, Ischaemic patients, Ischaemic stroke, Ischaemic strokes, John whitehead, Kjell asplund, Lancet, Lees, Liver function tests, Loading dose, Magnetic resonance imaging, Markku kaste, National institute, Neurological disorders, Neurological status, Neuroprotective, Neuroprotective drugs, Nihss, Nmda, Nmda receptor, Odds ratio, Patients randomised, Placebo, Placebo group, Plasma concentration, Primary analysis, Primary efficacy analysis, Primary efficacy population, Primary endpoint, Primary intracranial haemorrhage, Primary outcome, Primary outcome measure, Randomised, Rankin scale, Rankin score, Receptor, Secondary analyses, Secondary endpoints, Selective antagonist, Small proportion, Stratification variables, Stroke, Stroke onset, Stroke patients, Stroke severity, Study drug, Study medication, Target population, Thrombolytic therapy, Treatment groups, Video training.

Abstract

• https://api.istex.fr/document/A453AAAB355080042A656E2E0191178E1407454D/fulltext/pdf

Affiliations:

• Allemagne, Australie, Finlande, France, Italie, Royaume-Uni, Suède
• Aquitaine, Nouvelle-Aquitaine, Victoria (État)
• Bordeaux, Melbourne

Links toward previous steps (curation, corpus...)

• to stream Istex, to step Corpus: 001F14
• to stream Istex, to step Curation: 001F14
• to stream Istex, to step Checkpoint: 001F33
• to stream Main, to step Merge: 00CE13
• to stream PascalFrancis, to step Corpus: 005F16
• to stream PascalFrancis, to step Curation: 000254
• to stream PascalFrancis, to step Checkpoint: 005C67
• to stream Main, to step Merge: 00D215
• to stream Main, to step Curation: 00BF01

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00BF01 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00BF01 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A453AAAB355080042A656E2E0191178E1407454D
   |texte=   Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial
}}

This area was generated with Dilib version V0.6.33. Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024